Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus

doi:10.12092/j.issn.1009-2501.2026.05.006

Abstract

Abstract:

AIM: To investigate the clinical efficacy of liraglutide combined with metformin in overweight/obese patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 140 overweight/obese patients with T2DM admitted to the Department of Endocrinology of the First Affiliated Hospital of Anhui University Traditional Chinese Medicine were randomly divided into control group and observation group, with 70 cases in each. The control group was treated with metformin and routine diabetes diagnosis and treatment, and the observation group was treated with subcutaneous injection of liraglutide. The levels of glycolipid metabolism, carotid artery intima-media thickness (IMT), body mass index (BMI), and waist circumference (WC) and hip circumference (HC) were compared between the two groups after 12 weeks of treatment. The quality of life of patients was evaluated by Diabetes-Specific Quality of Life (DSQL). RESULTS: After 12 weeks of intervention, FPG, 2hPG, HbA1c, TC, TG, HDL-C, LDL-C and IMT in both the observation and control groups were significantly improved compared with those before treatment (P<0.05), and the observation group showed a better improvement than the control group. Although a statistically significant decrease in DSQL scores was evident in both groups after treatment (P<0.05), the improvement was significantly greater in the observation group than in the control group (P<0.05). In addition, after treatment, the weights, BMI, and WC and HC of the patients in both groups were significantly improved compared with those before treatment (P<0.05), and the group showed a better improvement in the level of obesity/overweight than the control group. During the treatment, the comparison of safety profiles revealed a similar incidence of adverse reactions between the two groups (P<0.05). CONCLUSION: Liraglutide combined with metformin can effectively improve the glycolipid metabolism of overweight/obese patients with type 2 diabetes, reduce carotid artery IMT, slow down the progression of atherosclerosis, improve the quality of life of patients, and does not increase incidence of adverse reactions, which provides new ideas and methods for clinical treatment.

Key words: liraglutide, metformin, overweight/obesity type 2 diabetes mellitus, glycolipid metabolism, carotid arteryima-media thickness, quality of life

CLC Number:

R587.1

Mei CHENG, Zhaohui FANG, Jindong ZHAO, Fengxia SHENG, Mengnan MA. Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 623-630.

Figures/Tables 6

References 30

1	李焱. 关注糖尿病管理过程中的体重控制[J]. 中国糖尿病杂志, 2023, 31 (5): 398- 400.
2	杨雁, 陈颖, 张惠杰, 等. 糖尿病患者体重管理专家共识(2024版)[J]. 中华糖尿病杂志, 2024, 16 (9): 959- 971.
3	Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: current concepts[J]. 世界糖尿病杂志: 英文版(电子版), 2023, 14 (4): 396- 411.
4	Arsenault BJ, Carpentier AC, Poirier P, et al. Adiposity, type 2 diabetes and atherosclerotic cardiovascular disease risk: use and abuse of the body mass index[J]. Atherosclerosis, 2024, 394, 117546. doi: 10.1016/j.atherosclerosis.2024.117546
5	中国2型糖尿病防治指南(2020年版)(上) [J]. 中国实用内科杂志, 2021, 41(8): 668-695.
6	刘莉娟, 曾红丽, 陈宇, 等. 达格列净联合二甲双胍治疗糖尿病肾病患者的临床研究[J]. 中国临床药理学杂志, 2025, 41 (9): 1207- 1212.
7	周英旎, 石敏, 赖敬波, 等. 聚乙二醇洛塞那肽联合二甲双胍治疗新诊断肥胖2型糖尿病[J]. 实用医学杂志, 2023, 39 (2): 170- 174.
8	宋白利, 付留俊, 常毅娜, 等. 利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响[J]. 中国药房, 2024, 35 (14): 1737- 1742. doi: 10.6039/j.issn.1001-0408.2024.14.11
9	杨梅, 王慧, 张圣武, 等. 利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效分析[J]. 中华全科医师杂志, 2021, 20 (4): 482- 484. doi: 10.3760/cma.j.cn114798-20200806-00884
10	林丹红, 全会标, 欧倩滢, 等. 利拉鲁肽对超重或肥胖男性2型糖尿病患者睾酮及性功能的影响[J]. 实用医学杂志, 2023, 39 (7): 894- 898.
11	Sadeghi A, Niknam M, Momeni-Moghaddam MA, et al. Crosstalk between autophagy and insulin resistance: evidence from different tissues[J]. Eur J Med Res, 2023, 28 (1): 456. doi: 10.1186/s40001-023-01424-9
12	Kurniawan LB, Apriani LP, Kadir NA, et al. Visceral fat as the main obesity index that determines the occurrence of adipose tissue insulin resistance[J]. EJIFCC, 2025, 36 (3): 321- 327.
13	Ortega MA, Fraile-Martínez O, Naya I, et al. Type 2 diabetes mellitus associated with obesity (diabesity). The central role of gut microbiota and its translational applications[J]. Nutrients, 2020, 12 (9): 2749. doi: 10.3390/nu12092749
14	Camacho-Padilla LG, Zepeda-Morales ASM, Arrizon J, et al. Preclinical evaluation of puerarin as a modulator of metabolic and inflammatory parameters in a high-fat-diet-fed mice model[J]. Molecules, 2025, 30 (19): 3895. doi: 10.3390/molecules30193895
15	Dutta S, Shah RB, Singhal S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes[J]. Drug Des Devel Ther, 2023, 17, 1907- 1932. doi: 10.2147/DDDT.S409373
16	刘建城, 吴淼, 余乐天, 等. 基于太赫兹波检测技术研究二甲双胍对生命状态的影响[J]. 中华中医药杂志, 2024, 39 (7): 3788- 3791.
17	Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss[J]. Curr Obes Rep, 2019, 8 (2): 156- 164. doi: 10.1007/s13679-019-00335-3
18	Love KM, Barrett EJ, Horton WB. Metformin's impact on the microvascular response to insulin[J]. Endocrinology, 2022, 163 (11): bqac162. doi: 10.1210/endocr/bqac162
19	周蓓, 李静, 方晨圆, 等. 二甲双胍/维格列汀和利拉鲁肽对肥胖合并2型糖尿病患者的临床疗效比较[J]. 南方医科大学学报, 2023, 43 (3): 436- 442.
20	Sandsdal RM, Juhl CR, Jensen SBK, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial[J]. Cardiovasc Diabetol, 2023, 22 (1): 41. doi: 10.1186/s12933-023-01765-z
21	邢英, 郑嵘炅, 姜春晖, 等. 利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性[J]. 中国临床药理学与治疗学, 2025, 30 (8): 1084- 1091. doi: 10.12092/j.issn.1009-2501.2025.08.009
22	杨林泉, 乔莉, 朱慧明, 等. 利拉鲁肽调控Cideb通路改善肝脏脂质沉积的作用研究[J]. 中国药学杂志, 2025, 60 (15): 1577- 1586.
23	Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes[J]. Lancet, 2022, 400 (10365): 1803- 1820. doi: 10.1016/S0140-6736(22)01655-5
24	刘云涛, 水芳芳, 张萌, 等. 利拉鲁肽对2型糖尿病合并颈动脉粥样硬化患者颈动脉内膜中层厚度及血清沉默信息调节因子6影响的研究[J]. 中国糖尿病杂志, 2025, 33 (2): 98- 103.
25	刘佐相, 陈晓薇, 赵厚宇, 等. 真实世界中2型糖尿病患者二甲双胍联用西格列汀的心血管安全性[J]. 北京大学学报(医学版), 2024, 56 (3): 424- 430.
26	Zhao Y, Jia X, Yang XY, et al. Deacetylation of caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation[J]. Metabolism, 2022, 131, 155162. doi: 10.1016/j.metabol.2022.155162
27	Nuamnaichati N, Mangmool S, Chattipakorn N, et al. Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac/PI3K/Akt pathway[J]. Front Pharmacol, 2020, 11, 805. doi: 10.3389/fphar.2020.00805
28	Chen SY, Wu JY, Liao KM, et al. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study[J]. Eur Heart J Cardiovasc Pharmacother, 2025, 11 (4): 324- 333. doi: 10.1093/ehjcvp/pvaf014
29	Deerochanawong C, Krittayaphong R, Romano JGU, et al. Cost-utility of liraglutide plus standard of care versus standard of care in people with type 2 diabetes and cardiovascular risk in Thailand[J]. Diabetes Ther, 2023, 14 (3): 531- 552. doi: 10.1007/s13300-023-01371-y
30	吴立华, 黄达, 冯青春. 利拉鲁肽联合达格列净治疗血糖控制不佳的老年2型糖尿病的疗效[J]. 中国老年学杂志, 2023, 43 (11): 2588- 2592.

Item	Control (n=70)	Treatment (n=70)
Gender (male/female)	47/23	44/26
Age/year	50.48±14.08	51.34±12.52
BMI (kg/m²)	30.92±1.76	30.86±1.68
HR (time/min)	84.23±6.28	85.28±6.26
SBP (mmHg)	138.56±7.28	137.68±7.28
DBP (mmHg)	78.68±6.84	77.82±8.46

Item	Control (n=70)	Treatment (n=70)
Gender (male/female)	47/23	44/26
Age/year	50.48±14.08	51.34±12.52
BMI (kg/m²)	30.92±1.76	30.86±1.68
HR (time/min)	84.23±6.28	85.28±6.26
SBP (mmHg)	138.56±7.28	137.68±7.28
DBP (mmHg)	78.68±6.84	77.82±8.46

Item	FPG (mmol/L)		2hPG (mmol/L)		HbA1c (%)
Item	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control	9.32±1.85	8.75±1.24	12.48±3.26	10.75±1.86	10.36±1.18	8.64±1.36
Treatment	9.30±1.76	6.72±1.36	12.30±2.36	6.58±1.58	10.24±1.25	6.50±1.52
t	0.049	6.976	0.283	3.216	0.182	12.02
P	0.960	0.000	0.7140	0.000	0.857	0.000

Item	FPG (mmol/L)		2hPG (mmol/L)		HbA1c (%)
Item	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control	9.32±1.85	8.75±1.24	12.48±3.26	10.75±1.86	10.36±1.18	8.64±1.36
Treatment	9.30±1.76	6.72±1.36	12.30±2.36	6.58±1.58	10.24±1.25	6.50±1.52
t	0.049	6.976	0.283	3.216	0.182	12.02
P	0.960	0.000	0.7140	0.000	0.857	0.000

Item	TC (mmol/L)		TG (mmol/L)		LDL-C (mmol/L)		HDL-C (mmol/L)		IMT (cm)
Item	Before Treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control	2.85±0.82	2.59±0.55^b	2.92±0.82	2.58±0.53^b	4.26±0.85	3.61±0.58^b	1.24±0.64	1.32±0.21^b	1.32±0.21	1.18±0.27^b
Treatment	2.82±0.51	2.02±0.36^b	2.89±0.45	2.04±0.16^b	4.28±0.76	2.32±0.42^b	1.23±0.54	1.86±0.52^b	1.30±0.28	0.86±0.24^b
t	0.196	5.486	0.203	6.400	0.111	11.395	0.076	5.217	0.361	5.604
P	0.844	0.000	0.840	0.000	0.912	0.000	0.940	0.000	0.720	0.000